GenoMed Names Dr. Kilmer McCully to Science Advisory Board; "Father of Homocysteine"
CONTACT: GenoMed Inc. David W. Moskowitz, MD, MA, FACP (314) 983-9933 dwmoskowitz@genomed.com
ST. LOUIS, MO. – October 28, 2004 – GenoMed, Inc. (Pink Sheets: GMED), a Next Generation DM™ (Disease Management) company that uses its expertise in genomics to improve clinical outcomes, announced today that it has named Dr. Kilmer S. McCully to its Science Advisory Board.
Dr. McCully is internationally recognized for discovering a link between homocysteine and heart disease beginning in 1969. It has been called a major scientific breakthrough of the past century.
In 1997 Dr. McCully authored his first book, The Homocysteine Revolution, which has been the subject of much media attention with articles appearing in the New York Times, Newsweek, Time, and several national health newsletters. In addition, he appeared on several national television programs, including NBC News, The Today Show, Fox News Healthline, 20/20 ABC Newsmagazine, and The View. He has authored several book chapters and 75 research articles. His second book, The Heart Revolution, was published in 1999.
He is the recipient of numerous prizes and awards, including the Linus Pauling Functional Medicine Award in 1998, the Special Achievement Award from the International Journal of Integrative Medicine in 2000, induction into the Twentieth Century Hall of Fame by Prevention Magazine in 2000, the Gallery of Heroes Award from Men’s Journal Magazine (2001), and the Integrity in Science Award from the Weston A. Price Foundation (2003).
From 1981 until 2001 Dr. McCully served as Pathologist at the Veterans Affairs Medical Center in Providence, Rhode Island. Prior to this position, Dr. McCully was Associate Pathologist at Massachusetts General Hospital and Assistant Professor of Pathology at Harvard Medical School. He is currently Chief of Pathology and Laboratory Medicine and Director of the Boston Area Consolidated Laboratories at the Veterans Affairs Medical Center in West Roxbury, Massachusetts. He is also serving as Associate Clinical Professor of Pathology at Harvard Medical School.
Dr. McCully said, "I am very excited to be associated with GenoMed and with my former student, David Moskowitz. Homocysteine may indeed activate ACE as Dr. Moskowitz has postulated, which would amplify its effects."
Said Dr. Moskowitz, "I am thrilled to be collaborating with my former teacher Kilmer S. McCully. Dr. McCully's research, under-appreciated for decades, is finally achieving the international acclaim which it deserves. I would not be in the least surprised if Dr. McCully were soon awarded the Nobel Prize."
About GenoMed
GenoMed is leading the clinical revolution which medical genomics has already made possible. GenoMed is a Next Generation DM(TM) (Disease Management) company whose mission is to improve clinical outcomes by identifying the genetic pathways that cause disease. GenoMed is currently marketing its protocol for delaying complications like kidney failure due to high blood pressure and diabetes. Eighty million Americans are at increased risk for kidney failure. GenoMed is also marketing its method for delaying emphysema, which 3 million Americans have, and another 60 million smokers are at increased risk of getting.
This fall and winter GenoMed is coordinating a nation-wide influenza trial using the Company's patent-pending protocol, which exploits already existing, FDA-approved drugs. Anyone can enroll simply by clicking on the "Flu trial" link at genomed.com.
|
